AstraZeneca Says Eplontersen Phase III Results Published In JAMA Showing Consistent And Sustained Benefit At 35, 66 And 85-Week Analyses; Consistent & Sustained Benefit On All Co-Primary, Secondary Endpoints In Patients With Diverse Range Of Diseases
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca has announced that the Phase III results of Eplontersen have been published in JAMA, showing consistent and sustained benefits at 35, 66, and 85-week analyses. The drug showed benefits on all co-primary and secondary endpoints in patients with a diverse range of diseases.
September 28, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Eplontersen Phase III results show consistent and sustained benefits, which could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given the consistent and sustained benefits shown by Eplontersen in Phase III trials, it's likely that this news will have a positive impact on AstraZeneca's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100